CellProtect Nordic Pharmaceuticals AB is located in Huddinge, Sweden on Hälsovägen 7. CellProtect Nordic Pharmaceuticals AB is rated 3 out of 5 in the category pharmaceuticals in Sweden. CellProtect Nordic Pharmaceuticals (CPNP) has developed a platform technology, CellProtect, an Advanced Medicinal Product based on autologous ex vivo expanded Natural Killer cells with restored cytotoxic activity. Currently, phase II studies are in preparation for the first indication Multiple Myeloma (MM). Safety and efficacy Phase I results are available. CellProtect has a unique mechanism of action different from the treatment regiments currently used. Considering the nature of CellProtect as an autologous cell therapy product it may be used as adjunct therapy to current clinical praxis and in combination with other therapies to expand the treatment options for an improved effect, a more stringent complete response, and curative potential. CPNP has been granted Orphan Drug Designation for the treatment of MM from the EC and are planning to advance the clinical development and reach the market via accelerated/conditional approval In CellProtect offers an adoptive immunotherapy with a potential to fulfil a high unmet medical need in MM patient populations representing different clinical stages of the disease.
Company size
1-10 employees